NCT01649284Approved For Marketing不适用
LUX-Lung EAP US; An Open Label Expanded Access Program of Afatinib (BIBW 2992) for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 试验地点
- 66
研究概览
简要总结
This is an open-label, multi-center, single-arm trial, designed to provide early access to afatinib and to provide additional information on the safety and efficacy of afatinib in advanced NSCLC patients who harbor an EGFR mutation.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (66)
Loading locations...
相似试验
No Longer Available
不适用
Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor TherapyNon-Small Cell Lung CancerNCT02271139Genentech, Inc.
已完成
3 期
Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR MutationCarcinoma, Non-Small-Cell LungNCT01953913Boehringer Ingelheim542
Approved For Marketing
不适用
An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer RefractoryMetastatic Breast CancerNCT01240421Eisai Inc.
Approved For Marketing
不适用
Expanded Access Study of Afatinib in Treatment-naive or Chemotherapy Pre-treated Patients With Non-small Cell Lung Cancer (NSCLC)Carcinoma, Non-Small-Cell LungNCT01931306Boehringer Ingelheim
Approved For Marketing
不适用
An Expanded Access Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing ChemotherapyUrothelial CarcinomaNCT02589717Genentech, Inc.